XASECHRO
Market cap3mUSD
Dec 23, Last price
0.64USD
1D
-0.54%
1Q
-17.63%
IPO
-86.67%
Name
Chromocell Therapeutics Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-7m
L+200.20%
CFO
-981k
L-37.40%
Profile
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||
Revenues | ||||
Cost of revenue | 9,442 | 2,710 | 1,048 | |
Unusual Expense (Income) | ||||
NOPBT | (9,442) | (2,710) | (1,048) | |
NOPBT Margin | ||||
Operating Taxes | (690) | (839) | ||
Tax Rate | ||||
NOPAT | (9,442) | (2,019) | (209) | |
Net income | (7,381) 200.20% | (2,459) 312.94% | (595) -9.87% | |
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 255 | |||
BB yield | ||||
| Debt | ||||
Debt current | 1,269 | 540 | ||
Long-term debt | 1,100 | |||
Deferred revenue | ||||
Other long-term liabilities | ||||
Net debt | 1,172 | 485 | 1,100 | |
| Cash flow | ||||
Cash from operating activities | (981) | (1,567) | (1,593) | |
CAPEX | 1 | |||
Cash from investing activities | ||||
Cash from financing activities | 1,022 | 1,622 | 1,593 | |
FCF | (7,432) | (1,434) | (965) | |
| Balance | ||||
Cash | 96 | 55 | ||
Long term investments | ||||
Excess cash | 96 | 55 | ||
Stockholders' equity | (13,520) | (6,138) | (3,680) | |
Invested Capital | 8,344 | 2,972 | 1,100 | |
ROIC | ||||
ROCE | 182.42% | 85.59% | 40.62% | |
| EV | ||||
Common stock shares outstanding | 5,768 | 5,768 | 5,768 | |
Price | ||||
Market cap | ||||
EV | ||||
EBITDA | (9,254) | (2,710) | (1,048) | |
EV/EBITDA | ||||
Interest | 519 | 140 | 253 | |
Interest/NOPBT | ||||